The Johnson & Johnson COVID-19 vaccine uses a harmless, modified cold virus to deliver genetic instructions into your cells, teaching your immune system to recognize and fight the SARS-CoV-2 spike protein. It was the only single-dose COVID-19 vaccine authorized in the United States, though its authorization was revoked in June 2023 after demand dropped and remaining doses expired. Understanding how it worked still matters if you received it or want to understand viral vector vaccine technology, which is being used against other diseases.
The Viral Vector Approach
Unlike the Pfizer and Moderna vaccines, which use mRNA wrapped in a fatty coating, the J&J vaccine relies on a viral vector: a real virus that has been gutted so it can’t replicate or make you sick. Specifically, it uses adenovirus type 26 (Ad26), a type of common cold virus. Scientists deleted the part of the adenovirus genome that allows it to copy itself, then inserted a gene encoding the SARS-CoV-2 spike protein into that empty slot.
When the vaccine is injected into your arm, the modified adenovirus enters your cells the same way a natural cold virus would. Once inside, it delivers its DNA payload to the cell’s nucleus. Your cell reads those instructions and begins manufacturing copies of the spike protein, the same mushroom-shaped protein that studs the surface of the real coronavirus and allows it to latch onto human cells. The spike protein gene was optimized to work efficiently in human cells, and the protein itself was locked into a “prefusion” shape, the exact form it takes before it attaches to a cell. This matters because antibodies trained against that shape are better at blocking actual infection.
Crucially, the adenovirus vector cannot reproduce. It delivers its cargo and is gradually broken down by the body. You never develop a cold from it, and it never integrates into your DNA.
How Your Immune System Responds
Once your cells start displaying spike proteins on their surfaces, your immune system treats them as foreign invaders and mounts a multi-layered defense. The vaccine triggers three key responses: neutralizing antibodies that can block the virus from entering cells, CD4+ helper T cells that coordinate the broader immune response, and CD8+ killer T cells that destroy infected cells directly.
This combination is important. Antibodies serve as the first line of defense, intercepting the virus before it gains a foothold. But T cells provide a deeper layer of protection, hunting down cells that the virus has already infiltrated. The J&J vaccine was specifically shown to produce a Th1-biased immune response, meaning the type of helper T cell activity it generates is well-suited to fighting viral infections rather than triggering the kind of allergic-type inflammation that would be counterproductive.
In healthy adults, this immune response provided meaningful protection against severe COVID-19 and hospitalization after a single shot. Protection against mild or asymptomatic infection was more modest, which is why boosters were later recommended.
Why One Dose Instead of Two
The single-dose design was one of the vaccine’s biggest practical advantages. The adenovirus vector delivers DNA rather than mRNA, and DNA is inherently more stable inside cells, producing spike protein over a somewhat longer window. This prolonged exposure gave the immune system more time to learn from a single injection. For large-scale vaccination campaigns, especially in rural areas or countries with limited cold-chain infrastructure, a one-dose vaccine was far simpler to deploy.
Storage was also easier. The J&J vaccine could be kept in a standard refrigerator at 2°C to 8°C (roughly 36°F to 46°F) without freezing. Compare that to the original mRNA vaccines, which required ultra-cold freezers at temperatures as low as minus 70°C. This made the J&J vaccine practical for pharmacies, mobile clinics, and remote settings where deep-freeze storage wasn’t available.
A Platform With a Track Record
The Ad26 vector wasn’t invented for COVID-19. Janssen (Johnson & Johnson’s pharmaceutical arm) had been developing vaccines on this same platform for years. The technology was already used in an authorized Ebola vaccine called Zabdeno, and Ad26-based vaccines had been tested in clinical trials for HIV, respiratory syncytial virus (RSV), and malaria. That history gave regulators and scientists a head start on understanding the platform’s safety profile and how the human immune system interacts with it.
One concern with adenovirus-based vaccines is that your body might develop antibodies against the vector itself, potentially reducing the effectiveness of future doses or other Ad26-based vaccines. Clinical data from Janssen’s various vaccine programs, however, did not show a clear negative impact from pre-existing anti-Ad26 antibodies on vaccine performance after individual doses.
The Blood Clotting Risk
The J&J vaccine was linked to a rare but serious side effect called thrombosis with thrombocytopenia syndrome (TTS), a condition involving unusual blood clots combined with low platelet counts. Through August 2021, after roughly 14.1 million doses were administered in the United States, the overall reporting rate was about 3.83 cases per million doses.
The risk was not evenly distributed. Women between the ages of 30 and 39 had the highest rate at 10.6 cases per million doses, followed by women aged 40 to 49 at 9.0 per million. Men had lower rates across all age groups, and men 65 and older had zero reported cases. For context, the risk was still very small in absolute terms, but it was high enough relative to alternatives that the CDC eventually recommended people preferentially choose an mRNA vaccine when one was available.
Boosters and Later Recommendations
As data accumulated showing that protection from the single J&J dose waned over time, the CDC recommended that all adults who received the J&J vaccine get a booster at least two months later. The preferred booster was a different vaccine type altogether: an mRNA shot from Pfizer or Moderna. This “mix-and-match” approach, called heterologous boosting, was found to produce a stronger immune response than a second J&J dose. A second J&J shot was only recommended if mRNA vaccines were unavailable or medically contraindicated.
Current Availability
The J&J COVID-19 vaccine is no longer available in the United States. In May 2023, Janssen voluntarily requested withdrawal of its emergency use authorization, citing expired government-purchased lots, no demand for new production, and no plans to update the vaccine’s strain composition to match newer variants. The FDA formally revoked the authorization on June 1, 2023. If you previously received the J&J vaccine, the updated mRNA vaccines are the recommended path for continued COVID-19 protection.